STARTUP PROFILE

Neurophet

COUNTRY
South-Korea
FOUNDED
2016
CATEGORY
Neuroimaging
Developing AI-driven neuroimaging software to analyze brain MRI scans for early detection and monitoring of neurodegenerative diseases.
Visit website →
Neurofounders Insights
$   Funding   -
Public
MODALITY
(f)MRI
FORM FACTOR
Software/app
INTERFACE DEPTH
Software
INDICATION
Multi-indication
TARGET USER
Clinicians
REGULATORY STAGE
FDA cleared (510k)
Neurophet is one of the more mature AI neuroimaging companies in Asia, applying MRI analysis to neurodegenerative disease detection and monitoring. Its public status and regulatory clearances give it greater commercial credibility than many newer imaging software entrants.
Mentioned in Market Notes
MOST RECENT COVERAGE
No items found.
Articles featuring
Neurophet
No items found.